Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - ATOSSA THERAPEUTICS, INC. | ex_167068.htm |
| EX-32.1 - EXHIBIT 32.1 - ATOSSA THERAPEUTICS, INC. | ex_167067.htm |
| EX-31.2 - EXHIBIT 31.2 - ATOSSA THERAPEUTICS, INC. | ex_167066.htm |
| EX-31.1 - EXHIBIT 31.1 - ATOSSA THERAPEUTICS, INC. | ex_167065.htm |
| EX-22.1 - EXHIBIT 22.1 - ATOSSA THERAPEUTICS, INC. | ex_167063.htm |
| EX-4.16 - EXHIBIT 4.16 - ATOSSA THERAPEUTICS, INC. | ex_178782.htm |
| 10-K - FORM 10-K - ATOSSA THERAPEUTICS, INC. | atos20191231_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Atossa Therapeutics, Inc.
Seattle, Washington
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (333-223949), Form S-3 (333-192390 and 333-220572), and Form S-8 (No. 333-185625 and 333-193952) of Atossa Therapeutics, Inc. of our report dated March 26, 2020, relating to the consolidated financial statements, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
|
/s/ BDO USA, LLP |
|
|
|
|
|
Seattle, Washington |
|
|
March 26, 2020 |
|